The anti-tau therapy demonstrated the strongest efficacy signal at the low 60mg Q6M dose.

Sarepta discontinued SRP-5051 development due to safety concerns, despite promising Phase 2 results in dystrophin expression and exon skipping. Persistent hypomagnesemia and declining kidney function ...

The deal gives Cellular Intelligence control of a clinical-stage therapy designed to restore the dopamine-producing nerve ...

SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the ...

Sept 10 (Reuters) - BridgeBio Pharma (BBIO.O), opens new tab said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland. The ...

Edward G. Neilan from NORD discusses critical efforts to speed up therapy development for rare diseases lacking treatments ...

Since 1921, when the first therapeutic peptide, insulin, was synthesized, many peptide-related accomplishments have reverberated throughout the industry, with more than 80 peptide drugs being approved ...

Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's cell therapy candidate for ...

Since the FDA first approved CAR-T cell therapy in 2017, eight CAR-T drugs have emerged, six of which have been fully approved by the FDA. This groundbreaking cell therapy has brought about a series ...